Böbrek Kanserinde İmmunoloji ve İmmunoterapiler
Özet
Böbrek kanseri, özellikle renal hücreli kanser (RHK), immünolojik sistem için potansiyel bir hedef olup tedavisinde immünoterapiler önemli rol oynamaktadır. 1990'larda interlökin-2 (IL-2) ve interferon-alfa gibi sitokin tedavileriyle başlayan süreç, ciddi yan etkilere ve sınırlı yanıt oranlarına (%10-15) sahipti. Sistemik tedavi öncesi sitoredüktif nefrektominin sağkalımı artırdığı kanıtlanmıştır. Son yıllarda, berrak hücreli RHK patogenezinde rol oynayan VHL/HIF aksını hedefleyen hedefe yönelik tedaviler geliştirilmiştir. 2006'da onaylanan tirozin kinaz inhibitörü Sunitinib, interferon-alfanın yerini alarak standart birinci basamak tedavi olmuştur. Günümüzde ise immün sistem kontrol noktası inhibitörlerinin (ICI) kombinasyonları tedavide yeni bir dönüm noktası oluşturmuştur. Ipilimumab/Nivolumab kombinasyonu mRHK'da onaylanan tek ikili ICI tedavisiyken; Axitinib/Pembrolizumab, Cabozantinib/Nivolumab ve Lenvatinib/Pembrolizumab gibi ICI ve tirozin kinaz inhibitörü (TKİ) kombinasyonları, yapılan Faz 3 çalışmalarda Sunitinibe kıyasla önemli ölçüde daha uzun progresyonsuz sağkalım (PFS) ve yüksek başarı oranları göstermiştir. Gelecekte ise HIF-2 alfa inhibitörleri, CD70A hedefli antikor-ilaç konjugatları ile belzutifan/lenvatinib (MK-6482-011) ve atezolizumab/cabozantinib (CONTACT-03) gibi yeni ajanların klinik pratiğe girmesi beklenmektedir. Sonuç olarak, metastatik RHK tedavisi sitokinlerden modern ICI/TKİ kombinasyonlarına evrilerek birinci basamakta çoklu seçenekler sunar hale gelmiştir.
Renal cell carcinoma (RCC) represents a crucial target for the immunological system, and its treatment landscape has evolved significantly since the 1990s introduction of cytokine therapies like interleukin-2 (IL-2) and interferon-alpha, which offered limited response rates and high toxicity. Cytoreductive nephrectomy prior to systemic therapy has been shown to improve median survival, establishing a standard sequence for metastatic RCC. Recent research focuses on clear cell RCC pathogenesis, specifically targeting the VHL/HIF pathway via vascular endothelial growth factor (VEGF) and mTOR inhibitors. Sunitinib, a tyrosine kinase inhibitor (TKI) approved in 2006, demonstrated superiority over interferon-alpha and became the first-line standard. Currently, immune checkpoint inhibitor (ICI) combinations mark a historical turning point; while the Ipilimumab/Nivolumab dual ICI combination offers durable responses, advanced Phase 3 trials show that combining ICIs with TKIs—such as Axitinib/Pembrolizumab, Cabozantinib/Nivolumab, and Lenvatinib/Pembrolizumab—significantly prolongs progression-free survival (PFS) compared to Sunitinib monotherapy. Emerging future therapies include oral HIF-2 alpha inhibitors, CD70A-targeted antibody-drug conjugates, and ongoing trials evaluating combinations like belzutifan plus lenvatinib or atezolizumab plus cabozantinib. In conclusion, metastatic RCC management has substantially expanded from early cytokines to highly effective first-line ICI/TKI combination regimens, providing diverse therapeutic options.
Referanslar
Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999:17:2530-2540.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65(1):5–29.
Uygur MC, Usubutun A, Ozen H, Ayhan A, Kendi S. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 1999;18(3):397–401.
McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high- dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients With metastatic renal cell carcinoma. J ClinOncol 2005; 23:133-41.
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J ClinOncol 2003; 21:3127-32.
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, re- combinant human interferon alfa-2a, or both in metastaticrenal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338:1272-8.
Mickisch GH. Urologic approaches to metastatic renal cell carcinoma. Onkologie. 2001 Apr;24(2):122-6
Rini BI, Campbell SC. The evolving role of surgery for advanced renal cancer in the era of molecular targeted therapy. J Urol 2007;177:1978-84.
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6;345(23):1655-9.
Mickisch GH, Garin A, van Poppel H, et al Radical nephrectomy plus interferon-alfabased immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet. 2001 Sep 22;358(9286):966-70.
Flanigan RC, Mickisch G, Sylvestor R. Cytoreductive nephrectomy in patients with metastatic renal cell cancer: A combined analysis. J Urol 2004;171:1071-6
Mickisch GH. Salvage surgery for advancer renal cancer. Eur Urol Suppl 2004;3:2-8
Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000:27:187-193.
Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon- alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999.17:2859-2867.
Ezekowitz HA, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life- threatening hemangiomas of infancy. N Engl J Med 1992:326:1456-1463.
Cantrell DA, Smith KA. The interleukin-2 T- cell system: a new cell growth model. Science 1984:224:1312
Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2007, 356, 115–124.
Ravaud, A.; Motzer, R.J.; Pandha, H.S.; George, D.J.; Pantuck, A.J.; Patel, A.; Chang, Y.-H.; Escudier, B.; Donskov, F.; Magheli, A.; et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N. Engl. J. Med. 2016, 375, 2246–2254.
Albiges, L.; Tannir, N.M.; Burotto, M.; McDermott, D.; Plimack, E.R.; Barthélémy, P.; Porta, C.; Powles, T.; Donskov, F.; George, S.; et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020, 5, e001079.
Rini, B.I.; Powles, T.; Atkins, M.B.; Escudier, B.; McDermott, D.F.; Suarez, C.; Bracarda, S.; Stadler, W.M.; Donskov, F.; Lee, J.L.; et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmo- tion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019, 393, 2404–2415.
Rini, B.I.; Atkins, M.B.; Escudier, B.; Powles, T.; McDermott, D.F.; Alekseev, B.Y.; Lee, J.-L.; Stroyakovskiy, D.; Rodriguez, C.S.; De Giorgi, U.; et al. Abstract CT188: IMmotion 151: Updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). Clin. Trials 2021, 81, CT188.
Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albiges, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019, 380, 1103–1115.
Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanov, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Alekseev, B.; Soulières, D.; Melichar, B.; et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019, 380, 1116–1127.
owles, T.; Plimack, E.R.; Soulières, D.; Waddell, T.; Stus, V.; Gafanov, R.; Nosov, D.; Pouliot, F.; Melichar, B.; Vynnychenko, I.; et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE- 426): Extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020, 21, 1563–1573.
Rini, B.I.; Plimack, E.R.; Stus, V.; Waddell, T.; Gafanov, R.; Pouliot, F.; Nosov, D.; Melichar, B.; Soulieres, D.; Borchiellini, D.; et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. J. Clin. Oncol. 2021, 39 (Suppl. 15), 4500.
Choueiri, T.K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M.T.; Zurawski, B.; Oyervides Juárez, V.M.; Hsieh, J.J.; Basso, U.; Shah, A.Y.; et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2021, 384, 829–841.
Motzer, R.; Alekseev, B.; Rha, S.-Y.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T.E.; Kopyltsov, E.; Méndez-Vidal, M.J.; et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N. Engl. J. Med. 2021, 384, 1289–1300
Cuvillier, O. The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. Transl. Androl. Urol. 2017, 6, 131–133.
Pal, S.K.; Forero-Torres, A.; Thompson, J.A.; Morris, J.C.; Chhabra, S.; Hoimes, C.; Vogelzang, N.J.; Boyd, T.; Bergerot, P.G.; Ba, J.J.A.; et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. Cancer 2019, 125, 1124–1132.
Merck Sharp & Dohme Corp. An Open-Label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs. Cabozantinib for Second-Line or Third-Line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed after Prior Anti-PD-1/L1 Therapy. Available online: https://clinicaltrials.gov/ct2/show/NCT04586231 (accessed on 23 August 2021).
ClinicalTrials.gov. A Study of Atezolizumab in Combination with Cabozantinib Compared to Cabozantinib Alone in Participants with Advanced Renal Cell Carcinoma after Immune Checkpoint Inhibitor Treatment (CONTACT-03). Available online: https: //www.clinicaltrials.gov/ct2/show/NCT04338269 (accessed on 18 August 2021).
